Bayer Healthcare LLC

Bayer Pharmaceuticals Corporation

Bayer Pharma Aktiengesellschaft

Stephen Boyer

Jacques P Dumas

Dhanapalan Nagarathnam

Wendy Lee

Ning Miao Su

William Johnston Scott

Barton W Phillips

Robert Sibley

Holia Hatoum-Mokdad

Harold C E Kluender

Teddy Kite Joe

Jianqing Chen

Roger Astbury Smith

Gan Wang

Olaf Weber

Yuanwei Chen

Jianmei Fan

Julie A Dixon

Zhi Chen

Aniko Redman

Sharad Verma

Qingming Zhu

Chunguang Wang

Lin Yi

Lila Adnane

Jianxing Shao

Karl-Heinz Schlemmer

Achim Feurer

Bernd Riedl

Benjamin Jones

Paul Naab

Uday R Khire

Marcus Bauser

Nils Burkhardt

Dietmar Flubacher

Jens-Kerim Ergüden

Brian Raudenbush

Hans Pluempe

Samir Bennabi

Jennifer Burke

Maria Niewöhner

Jürgen Stoltefuss

Davoud Asgari

Scott Wilhelm

Karl Miranda

Michael Schauer

Barry Hart

Mark Lynch

Xiao-Gao Liu

Dhanaphalan Nagarathnam

Mark Miglarese

Andrea Sewing

Thorsten-Oliver Repp

Donald Bankston

David Cantin

Sidney X Liang

A compound of Formula (I): salts thereof, prodrugs thereof, metabolites thereof, pharmaceutical compositions containing such a compound, and use of such compound and compositions to treat diseases mediated by raf, VEGFR, PDGFR, p38 and flt-3.

Fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions

This invention relates to novel diaryl ureas, pharmaceutical compositions containing such compounds and the use of those compounds or compositions for treating hyper-proliferative and angiogenesis disorders, as a sole agent or in combination with cytotoxic therapies.

Bicyclic urea derivatives useful in the treatment of cancer and other disorders

Substituted and pyridines and pyridazines having angiogenesis inhibiting activity and the generalized structural formula wherein the ring containing A, B, D, E, and L is phenyl or a nitrogen-containing heterocycle; groups X and Y may be any of a variety of defined linking units; Rand Rmay be defined independent substituents or together may be a ring-defining bridge; ring J may be an aryl, pyridyl, or cycloalkyl group; and G groups may be any of a variety of defined substituents. Pharmaceutical compositions containing these materials, and methods of treating a mammal having a condition characterized by abnormal angiogenesis or hyperpermiability processes using these materials are also disclosed.

Substituted pyridines and pyridazines with angiogenesis inhibiting activity

2-oxo-1,3,5-perhydrotriazapine derivatives useful in the treatment of hyper-proliferative, angiogenesis, and inflammatory disorders

A process for the preparation of various quinazoline compounds which are useful as Rho-Kinase inhibitors, and thus having utility in the treatment of hypertension and other indications.

Process for preparing quinazoline Rho-kinase inhibitors and intermediates thereof

Cyanopyridine derivatives useful in the treatment of cancer and other disorders

Disclosed are compounds and derivatives thereof, their synthesis, and their use as Rho-kinase inhibitors. These compounds are useful for inhibiting tumor growth, treating erectile dysfunction, and treating other indications mediated by Rho-kinase, e.g., coronary heart disease.

Rho-kinase inhibitors

The present invention relates to pyrrolo[2.1-a]dihydroisoquinolines which are inhibitors of phosphodiesterase 10a and can be used for combating cancer.

Pyrrolo (2.1a)dihydroisoquinolines and their use as phosphodiesterase 10a inhibitors

Substituted and Fused pyridazines having angiogenesis inhibiting activity and the generalized structural formulawherein the ring containing A, B, D, E, and L is a nitrogen-containing heterocycle; groups X and Y may be any of a variety of defined linking units; Rand Rmay be defined independent substituents or together may be a ring-defining bridge; ring J may be an aryl, pyridyl, or cycloalkyl group; and G groups may be any of a variety of defined substituents. Pharmaceutical compositions containing these materials, and methods of treating a mammal having a condition characterized by abnormal angiogenesis or hyperpermiability processes using these materials are also disclosed.

Substituted pyridazines and fused pyridazines with angiogenesis inhibiting activity

Growing community of inventors

Fairfield, CT, United States of America

Stephen Boyer